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Abstract
Context: Although family studies have shown that male lower urinary tract symptoms
(LUTS) are highly heritable, no systematic review exists of genetic polymorphisms tested
for association with LUTS.
Objective: To systematically review and meta-analyze studies assessing candidate
polymorphisms/genes tested for an association with LUTS, and to assess the strength,
consistency, and potential for bias among pooled associations.
Evidence acquisition: A systematic search of the PubMed and HuGE databases as well as
abstracts of major urologic meetings was performed through to January 2013. Case-
control studies reporting genetic associations in men with LUTS were included.
Reviewers independently and in duplicate screened titles, abstracts, and full texts to
determine eligibility, abstracted data, and assessed the credibility of pooled associations
according to the interim Venice criteria. Authors were contacted for clariﬁcations if
needed. Meta-analyses were performed for variants assessed in more than two studies.
Evidence synthesis: We identiﬁed 74 eligible studies containing data on 70 different
genes. A total of 35 meta-analyses were performed with statistical signiﬁcance in
ﬁve (ACE, ELAC2, GSTM1, TERT, and VDR). The heterogeneity was high in three of these
s73
4; 9meta-analyses. The r
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(I2 = 27.2%). No evidence for publication bias was identiﬁed. Limitations include wide-
ranging phenotype deﬁnitions for LUTS and limited power in most meta-analyses to
detect smaller effect sizes.
Conclusions: Few putative genetic risk variants have been reliably replicated across
populations. We found consistent evidence of a reduced risk of LUTS associated with the
common rs731236 variant of the vitamin D receptor gene in our meta-analyses.
Patient summary: Combining the results from all previous studies of genetic variants
that may cause urinary symptoms in men, we found signiﬁcant variants in ﬁve genes.
Only one, a variant of the vitamin D receptor, was consistently protective across different
populations.
# 2014 TheAuthors. Published by Elsevier B.V. on behalf of EuropeanAssociation ofUrology.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/3.0/).
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Lower urinary tract symptoms (LUTS) in men are catego-
rized into storage symptoms (increased daytime urinary
frequency, nocturia, urgency, and incontinence), voiding
symptoms (slow stream, splitting or spraying, intermittent
stream, hesitancy, straining, and terminal dribble), and
postmicturition symptoms (feeling of incomplete emptying
and postmicturition dribble) [1,2]. LUTS are highly preva-
lent and often bothersome. They are strongly associated
with both age and obesity [3–5], which is therefore likely to
increase future associated costs and burden.
Particularly when considering older men, a variety of
terms have been used historically to describe LUTS
including symptomatic benign prostatic hyperplasia (BPH),
symptomatic benign prostatic enlargement (BPE), or symp-
tomatic bladder outlet obstruction [6]. However, only a
minority of men with histologic evidence of BPH develop
significant bothersome LUTS, and among men presenting
with LUTS, only a minority have obstruction [6]. With
increasing focus on medical therapies targeting either the
bladder or prostate [7], the non–organ-specific term LUTS
has therefore been recommended, emphasizing themultiple
potential etiologies for these symptoms.
There is substantial evidence of familial aggregation of
male LUTS. Early reports identified very large excess risks
for the surgical treatment of LUTS among men with so-
called familial BPH [8]. However, subsequent work has
suggested more modest familial risks for the symptoms
themselves [9,10]. In the Olmsted County study, having
either a father or a brother with a history of diagnosed BPE
was associatedwith anodds ratio (OR) of 1.5 (95% confidence
interval [CI], 1.1–1.7) formoderate to severe LUTS at baseline
[9]. In the Krimpen study, reporting any first- or second-
degree relative with a diagnosis of prostate cancer was
associated with a hazard ratio of 1.7 (95% CI, 1.1–2.5) for
incident LUTS over amedian of 6.5 yr of follow-up [10]. Such
risks seem to be cumulative, with two or more affected
relatives conferring greater risk [11].
Twin studies provide estimates of heritability that
are less confounded by environmental or lifestyle factors
that may be shared within families. In a study of 256 twin
pairs enrolled in the US military, heritability was estimated
at 49% using a case definition corresponding to diagnosis
and/or treatment for BPH [12]. In a population-based study
of 83 twin pairs, the heritability of the American UrologicalAssociation Symptom Index (AUA-SI) was estimated at
39% overall, but with a higher heritability of 83% for men
>50 yr of age [13]. In a further population-based study of
3446 elderly male twins, heritability of moderate to severe
LUTS (again assessed using the AUA-SI) was estimated at
72% [14]. Taken together, these twin studies suggest similar
heritability as for many complex diseases for which the
genetic architecture is well understood, including prostate
cancer, where heritability has been estimated at between
42% [15] and 58% [16].
Many of the studies available for this review aimed
primarily to explore the molecular genetics of prostate
cancer rather than LUTS, but they included men with and
without LUTS as separate subgroups of controls. It remains
unclear whether LUTS or BPH might be risk factors for
prostate cancer. There is conflicting data regarding any
association of a diagnosis of LUTS/BPH with a subsequent
diagnosis of prostate cancer [17–20]. Evidence of a
consequent increase in high-risk cancers or prostate cancer
mortality is also mixed. Those studies that have suggested a
positive association may be unable to exclude detection
bias and unmeasured confounding from shared environ-
mental or genetic risk factors.
With pharmaceutical options for the prevention of
prostate cancer and LUTS [21], and an expanding array of
conservative options for managing LUTS, clinical risk
stratification may become more relevant than ever.
Robustly replicated genetic variants associated with LUTS
would provide useful information in assessing both
prognosis and potentially treatment response. Equally
importantly, new insights into the molecular genetics of
LUTS could help explain the underlying pathogenesis and
also offer future routes toward new drug targets.
The aim of this systematic review was to assess which
candidate polymorphisms and/or candidate genes had been
tested for an associationwith LUTS inmen, and to assess the
strength, consistency, and potential for bias among pooled
associations.
2. Evidence acquisition
2.1. Eligibility criteria
The review protocol was prospectively registered (PROS-
PERO 2011: CRD42012001985). We prespecified inclusion
of both case-control and cross-sectional designs, with both
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We included association studies testing for any genetic
polymorphism at the nucleotide level including single
nucleotide polymorphisms (SNPs), deletions, duplications,
and copy-number variants but excluded larger microscopic
variants at the karyotype level.
For LUTS, there are no gold standard diagnostic methods
because these are largely symptomatic diagnoses. We
therefore expected to accept case definitions or criteria
for LUTS as specified within each study, recognizing there
would be heterogeneity in definitions across studies. We
planned to include case definitions based on validated
symptom questionnaires, clinical evaluation, or urody-
namics. After conducting initial searches, we expanded this
to case definitions based on care seeking, including the use
of relevant medications (eg, a-blockers or anticholinergics)
or a history of relevant surgery including transurethral
resection of the prostate. We excluded studies using solely
histologic BPH or clinical BPE case definitions where LUTS
were not an inclusion criterion, for example studies based
on samples of asymptomatic men undergoing prostate
cancer screening. We considered the population of interest
as men 18 yr of age.
2.2. Search strategy
We combined searches from PubMed, HuGE Navigator, and
an extensive selection of urologic conference reports. We
searched PubMed up to January 2013 without language
restrictions, using a combination of genetic and phenotype
keywords and Medical Subject Headings (MeSH) terms:
(polymorphism OR SNP OR CNV OR ‘‘copy number variation’’
ORmutation OR genetic OR chromosome OR VNTR OR InDel OR
microsatellite) AND (‘‘benign prostatic enlargement’’ OR BPE
OR ‘‘benign prostatic hyperplasia’’ OR ‘‘bladder outflow
obstruction’’ OR BPH OR nocturia OR LUTS OR incontinence
OR urgency OR ‘‘overactive bladder’’ OR ‘‘Lower Urinary Tract
Symptoms’’[Mesh] OR ‘‘Urinary Incontinence’’[MeSH] OR
‘‘enuresis’’[Mesh]) NOT mitral NOT carcinoma[Title] NOT
cancer[Title] NOT (animals[mh] NOT humans[mh])
We searched HuGE Navigator, also through to January
2013, using the following phenotype indexing terms:
(‘‘prostatic diseases’’ OR ‘‘prostatic hyperplasia’’ OR ‘‘urina-
tion disorders’’ OR ‘‘nocturia’’ OR ‘‘urinary incontinence’’ OR
‘‘urinary bladder, overactive’’).
In addition we searched conference abstracts for annual
meetings of the American Urological Association, European
Association of Urology, International Urogynecological
Association, and International Continence Society from
2005 to 2012.
2.3. Screening and data extraction
We developed standardized data forms, and conducted
pilot screening and data extraction training exercises to
achieve a high level of consensus between reviewers. All
screening and data extractionwas performed independently
and in duplicate by methodologically trained reviewers.
Reviewers screened study reports by first screening titlesand abstracts to select papers for full-text assessment and
then screening full-text papers to confirm eligibility of the
articles. Screening discrepancieswere resolved bydiscussion
and adjudication. We hand-searched reference lists of all
included articles, applying the same standardized screening
process. When more than one published or unpublished
report was identified for the same association in the same
study population, we included the paper or abstract with the
largest sample size.
We contacted study authors by e-mail for clarifications,
additional information about methodology, and for addi-
tional subgroup analyses where necessary. Data extracted
included information on the setting for each study, details
of the sampling strategy and sampled populations (age,
ethnic/racial composition, and body mass index), the
overall sample size and proportion genotyped, the outcome
assessments used and phenotypic definitions, the genotyp-
ing method used, and the genotyping quality control
methods applied.Where possible we extracted or requested
from authors full genotype frequencies among both cases
and controls.
2.4. Statistical analysis and risk of bias assessments
For polymorphisms assessed in at least two studies for the
same phenotype, we conducted meta-analyses using the
‘‘metan’’ package (Stata v.12.1; StataCorp, College Station,
TX, USA). For meta-analyses with only two studies, or for
three or more studies and low heterogeneity, we used fixed
effects models but otherwise used random effects models.
In the absence of a clear rationale supporting any specific
model of inheritance, we used the allelic association test,
corresponding to codominant modes of inheritance for all
polymorphisms. We assessed the credibility of pooled
associations using the interim Venice criteria [22] that rates
pooled associations as weakly, moderately, or strongly
credible (see summary in Supplemental Fig. 17). We used
the Cochran Q test and the I2 statistic as measures of
between-study heterogeneity. We retested for departure
from the Hardy-Weinberg equilibrium among controls. We
assessed the risk of bias in phenotype definitions, genotyp-
ing, and population stratification.We used the Harbord [23]
and Egger [24] tests of funnel plot asymmetry to investigate
possible reporting biases. Reporting of the review complies
with recommendations both of the HuGE Handbook [25]
and the Preferred Reporting Items for Systematic Reviews
and Meta-analysis statement [26].
3. Evidence synthesis
We screened 1025 abstracts and retrieved 191 full texts
(Fig. 1). A total of 74 study reports provided data (Table 1)
regarding polymorphisms in or near 70 different genes
(Supplemental Table 1).We found no relevant genome-wide
association studies (GWAS) for male LUTS, with all included
studies using a candidate gene approach. Most research
interest has focused on variation in genes implicated in
steroid metabolic processes, inflammatory response, and
cytokine activity (Supplemental Table 2).Withmany studies
[(Fig._1)TD$FIG]
Duplicate study reports excluded: n = 7 
Study reports excluded after title and 
abstract review: n = 834  
Study reports excluded due to failure 
to satisfy inclusion criteriab: n = 105 
n = 1025 
searches in PubMed, HuGE 
abstractsa
Study reports for title and 
abstract screening: 
Navigator, and conference 
Keyword and index term 
Total studies included n = 74
Further studies excluded due to lack of 
usable datac: n = 5
Study reports retrieved for 
full-text evaluation: n = 191
Fig. 1 – Flowchart outlining the literature search and article evaluation
process.
a International Continence Society, International Urogynecological
Association, American Urological Association, and European Association
of Urology abstracts 2005–2012, using search interfaces at http://
www.icsoffice.org/Abstracts/, http://www.sciencedirect.com/science/
journal/15699056, http://www.jurology.com/supplements, and/or full-
text search of abstract book PDFs.
b Includes studies enrolling only women (n = 32), only children (n = 2),
reviews or letters (n = 12), inapplicable phenotypes such as prostate
cancer/prostate-specific antigen/benign prostatic enlargement/histologic
benign prostatic hyperplasia (n = 47), cohort study reports (n = 5), and
other study designs including pharmacogenetic studies, gene expression
studies, and polymorphic protein studies (n = 4).
c Authors contacted by e-mail for additional data from 37 studies.
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investigation, therewas also a significant overrepresentation
of genes implicated in the regulation of cell proliferation and
apoptosis. Only two studies considered specific LUTS [27,28],
with all other studies addressing a composite definition of
male LUTS suggestive of BPH.
Quantitative syntheses were possible for 35 polymor-
phisms in or near 24 genes (Table 2). Only 5 of these 35
meta-analyses achieved statistical significance (p < 0.05)
(ACE rs4340, ELAC2 rs5030739, GSTM1 null allele, TERT
rs2736098, and VDR rs731236), and of those only the
rs731236 polymorphism of VDR could be assigned moder-
ate epidemiological credibility (Fig. 2). The other statisti-
cally significant pooled associations were assigned weak
credibility, either because of low sample sizes, high
heterogeneity, or unaccounted sources of bias. In the
following section we focus only on genes with at least
one variant with a significant pooled association (reported
in alphabetical order). Nonsignificant pooled estimates for
all other genes are shown in Table 2 together with bias
estimates. Corresponding forest plots are available as
Supplemental Figures 1–16. A priori all nonsignificant
pooled estimates were assigned weak epidemiological
credibility.3.1. ACE
rs4340 is an extensively studied insertion polymorphism in
the angiotensin-converting enzyme gene. Although it has
been suggested as a risk factor for both cardiovascular
disease and a range of cancers, the most recent systematic
review suggests no overall association with prostate cancer
[29]. Two studies in Mexican [30] and Indian [31] popula-
tions assessed associations with LUTS or surgery for LUTS,
reporting a large protective effect of the insertion (pooled
OR: 0.66; 95% CI, 0.49–0.90) but with high heterogeneity
(I2 = 91.9%) (Fig. 3). Following the recommendations of
the Venice guidelines [22], the association was therefore
assigned weak credibility.
3.2. ELAC2
The rs5030739 polymorphism of ELAC2 was one of the
earliest candidates as a prostate cancer risk SNP [32]. Four
studies investigated an association of rs5030739 with
symptomatic BPH [33–36]. However, the risk SNPwas found
only among the two available European samples. In these
Finnish and Turkish populations, the minor A allele was
associatedwith a large increase in risk (pooledOR: 1.75; 95%
CI, 1.22–2.49),withnoheterogeneity (Fig. 4). Therewas a low
riskofbias fromgenotypingerrororpopulationstratification.
However, the meta-analysis included a low total sample of
participants with the minor allele (n = 71), and accordingly,
the association was assigned weak credibility. Analysis of a
different SNP, rs4792311, in ELAC2 in the same four studies
showed nonsignificant results in all samples and no
significant pooled association (Fig. 4).
3.3. GSTM1
The glutathione S-transferase M1 gene lies on chromosome
1 in a region with a number of common large-scale
structural variants in both Asian and European populations
that may delete one or both copies of the gene (null allele).
The gene encodes a cytoplasmic glutathione S-transferase,
involved in the detoxification of a range of compounds
including potential carcinogens. Current evidence suggests
the null allele is significantly associated with prostate
cancer [37]. We identified the same six studies, all of Indian
populations, included in a recent meta-analysis [38], with a
large effect size (pooled OR: 2.08; 95% CI, 1.37–3.16) but
with high heterogeneity (I2 = 74.3%) (Fig. 5). Although we
did not identify a significant source of bias, the high
heterogeneity again confers weak credibility.
3.4. TERT
Telomerase reverse transcriptase is a catalytic subunit of
telomerase that delays apoptosis. Both intronic and
noncoding variants in TERT have been identified as prostate
cancer risk SNPs in recent GWAS [39,40]; the rs2736098
noncoding SNP has also been associated with prostate-
specific antigen (PSA) variation [41]. Two large Icelandic
and US studies [41,42], including in combination >28 000
Table 1 – Included studies
Study Country Descent/
ethnicity/race*
Gene
symbols(s)
Polymorphism(s)
dbSNP ID or
other identiﬁer
LUTS case deﬁnition
1: Validated
questionnaire
2: BOO surgery
3: Nonvalidated
assessment
4: Care seeking
Additional
assessment(s)
1: DRE
2: PSA
3: TRUS
4: Histology
5: Flow studies
Ashtiani et al. [58] Iran Iranian AR
GSTM1
GSTT1
CAG repeat
Null genotype
Null genotype
3, 4 2, 3, 4
Berhane et al. [59] India North Indian ERCC5 XRCC1 rs17655
rs25487
3 4
Bid et al. [31] India Indian ACE rs4340 1, 4 1, 2, 3
Biolchi et al. [60] Brazil >80% white AR CAG repeat 3, 4 1, 3, 4
Biolchi et al. [61] Brazil >80% white AR GGC repeat 3, 4 1, 3, 4
Bousema et al. [46] Netherlands Dutch VDR rs731236 3, 4 1, 2, 5
Chaimuangraj et al. [49] Thailand Thai VDR rs731236
rs1544410
rs7975232
2, 3, 4 2, 4
Choubey et al. [38] India Indian GSTM1
GSTT1
Null genotype
Null genotype
1, 4 2, 3
Faria et al. [62] Brazil Brazilian TGFB1 rs1800471
rs1800470
2 4
Giovannucci et al. [52] USA Mixed US AR CAG repeat 1, 2 1, 4
Giovannucci et al. [53] USA Mixed US AR CAG repeat 2 4
Gudmundsson et al. [41] Iceland Icelandic TERT
MSMB
FGFR2
TBX3
HNF1B
KLK3
rs2736098y
rs401681
rs10993994
rs10788160
rs11067228
rs4430796
rs17632542
rs2735839
2, 4
Gunes et al. [63] Turkey Turkish KLK3
CYP17A1
rs266882
rs743572
2, 3, 4 4
Gupta et al. [64] India Indian ESR1 rs9340799
rs2234693z
4 2, 4
Habuchi et al. [65] Japan Japanese CYP17A1 rs743572 3, 4 1, 2
Habuchi et al. [47] Japan Japanese VDR rs731236
rs1544410
rs7975232
3, 4 1, 2
Hamasaki et al. [48] Japan Japanese VDR rs731236 3, 4 1, 2, 3
Helﬂand et al. [42] USA White RP11-382A18.1
TERT
MSMB
FGFR2
TBX3
HNF1B
KLK3
rs1447295y
rs6983267
rs2736098
rs401681
rs10993994
rs10788160
rs11067228
rs4430796
rs17632542
rs2735839
1, 4 2, 5
Ho et al. [66] Scotland White FGFR4 rs351855 4
Huang et al. [67] Taiwan Taiwanese VDR rs10735810 1, 3, 4 1, 2, 3
Huang et al. [68] Taiwan Taiwanese TP53
CDKN1A
rs1042522
rs1801270
1, 3, 4 1, 2, 3
Izmirli et al. [35] Turkey Southern Turkish SRD5A2
ELAC2
rs523349
rs9282858
rs4792311
rs5030739
4
Jero´nimo et al. [69] Portugal Unclear GSTP1 rs1695 2, 4 4
Kamoto et al. [70] Japan Japanese CDH1 rs16260 3, 4 1, 2
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Table 1 (Continued )
Study Country Descent/
ethnicity/race*
Gene
symbols(s)
Polymorphism(s)
dbSNP ID or
other identiﬁer
LUTS case deﬁnition
1: Validated
questionnaire
2: BOO surgery
3: Nonvalidated
assessment
4: Care seeking
Additional
assessment(s)
1: DRE
2: PSA
3: TRUS
4: Histology
5: Flow studies
Kesarwani and Mittal [71] India North Indian IL1B
TNF
IFNG
IL1RN
IL4
IL6
Il10
TGFB1
rs16944
rs1800629
rs1799964
rs1800630
rs1799724
rs2430561
rs2234663
rs2234664
rs2069840
rs1800896
rs1800871
rs1800470
1, 4 1, 2, 4
Konwar et al. [72] India North Indian IL4
IL1RN
rs2234664
rs2234663
1, 4 1, 2, 3, 4
Konwar et al. [73] India North Indian GSTT1
GSTM1
GSTP1
Null genotype
Null genotype
rs1695
1, 4 1, 2, 3, 5
Kristal et al. [74] USA >90% white AR CAG repeat 1 1, 2
Kumar et al. [75] India White Aryan GSTT1
GSTM1
Null genotype
Null genotype
3, 4 1, 2, 3, 4
Kumazawa et al. [76] Japan Japanese CYP11A1 (TTTTA)n 3, 4 1, 2
Li et al. [77] Sweden/Japan Swedish/Japanese AR CAG repeat 3, 4 1, 2, 3
Li et al. [78] Japan Japanese SRD5A2 rs523349
rs9282858
3, 4 1, 2, 3
Li et al. [79] Japan Japanese TGFB1 rs1800470 3, 4 1, 2, 3
Licastro et al. [80] Italy Italian SERPINA3 rs1884082 3, 4 1, 2, 3
Ma et al. [81] Japan Japanese FGFR4 rs2011077
rs351855
1, 3, 4 1, 2, 3
Madigan et al. [82] China Chinese CYP17 rs743572 2, 4 1, 2, 4
Manchanda et al. [50] India North Indian VDR rs731236
rs1544410
rs10735810
1, 4 1, 2, 3
Mitsumori et al. [83] Japan Japanese AR CAG repeat 2, 4 4
Mittal et al. [84] India North Indian IL1RN rs2234663 4 2, 3, 4
Mittal et al. [85] India North Indian GSTM1
GSTT1
GSTM3
Null genotype
Null genotype
rs1799735
1, 4 1, 2, 4
Mononen et al. [86] Finland Finnish AR CAG repeat 4 3, 5
Mononen et al. [87] Finland Finnish SRD5A2 rs9282858 4 3, 5
Narita et al. [88] Japan Japanese LPL rs254
rs316
rs328
3, 4 1, 2, 3
Nikolic´ et al. [89] Serbia Serbian Intergenic rs3787016 3, 4 1, 2, 3
Omrani et al. [90] Iran Iranian TGFB1 rs1800470 4 1, 2, 4
Omrani et al. [91] Iran Iranian IL10
IFNG
TNF
rs1800896
rs2430561
rs1800629
4 1, 2
Rajender et al. [92] India South Indian SRD5A2 rs523349
rs9282858
TA(n) repeat
4 1, 2
Ro¨kman et al. [33] Finland Finnish ELAC2 rs5030739
rs4792311
rs119484087
3, 4 2, 3
Ro¨kman et al. [93] Finland Finnish RNASEL rs486907
rs74315364
rs627928
rs145787003
3,4 2, 3, 5
Safarinejad et al. [94] Iran White IGFBP3 rs2854744 1, 4 1, 2, 3, 5
Salam et al. [95] USA Mixed US SRD5A2 rs523349
rs9282858
TA(n) repeat
1 1, 2
Schwanke et al. [28] Brazil Mixed Brazilian HTR2A rs6313 3
Seppa¨la¨ et al. [96] Finland Finnish KLF6 rs3750861 3, 4 1, 2, 3, 5
Shibata et al. [97] Japan Japanese ADRA1A rs1048101 3, 4 1
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Table 1 (Continued )
Study Country Descent/
ethnicity/race*
Gene
symbols(s)
Polymorphism(s)
dbSNP ID or
other identiﬁer
LUTS case deﬁnition
1: Validated
questionnaire
2: BOO surgery
3: Nonvalidated
assessment
4: Care seeking
Additional
assessment(s)
1: DRE
2: PSA
3: TRUS
4: Histology
5: Flow studies
Sierra Diaz et al. [30] Mexico Mexican ACE
AGTR1
rs4340
rs5186
2, 4 4
Sobti et al. [98] USA North Indian ESR1
SRD5A2
KLK3
CYP17
rs2234693z
TA(n) repeat
rs266882
rs743572
1, 4 2, 4
Sobti et al. [36] India North Indian ELAC2
SERPINA1
rs4792311
rs5030739
rs28929474
rs17580
1, 4 2, 4
Steiner et al. [99] Germany White NQO1 rs1800566 2 4
Takeda et al. [27] Japan Japanese ADRA1A
ADRB3
rs1048101
rs4994
3, 4
Takahashi et al. [100] Japan Japanese ELAC2 rs4792311
rs5030739
rs78105154
4
Tanaka et al. [101] Japan Japanese COMT rs4633
rs4680
rs6267
2,4 2, 4
Tanaka et al. [102] Japan Japanese MLH1 rs28930073
rs1799977
rs63750447
p.Ala723Asp
2,4 2, 4
Teitsma et al. [103] Netherlands Mixed ADRB3 rs4994 1,4 2, 3, 5
Terada et al. [104] Japan Japanese RP11-382A18.1 rs1447295
rs6983267
3,4 1, 2, 3
Thakur et al. [105] India Indian GSTT1
GSTM1
Null genotype
Null genotype
4 1
Tigli et al. [106] Turkey Turkish CYP17 rs743572 4
Tsuchiya et al. [107] Japan Japanese IGF1 CA repeat 2, 3, 4 1, 2, 4
Vijayalakshmi et al. [108] India South Indian AR CAG repeat
GGC repeat
4 1, 2, 4
Wang et al. [109] Japan Japanese CCND1 rs9344 2, 3 1, 2
Wang et al. [110] Japan Japanese IGFBP3 rs2854744 3, 4 1, 2
Wang et al. [111] Japan Japanese KLK3 rs266882
rs4802754
3, 4 1, 2
Yoo et al. [112] Korea Korean NOS2 rs2779248
rs10459953
rs2297518
3, 4 2
Yoo et al. [113] Korea Korean IL10
IL10RA
IL10RB
rs1518111
rs1554286
rs2256111
rs4252243
rs2228054
rs999788
rs2834167
3, 4 2
Zhenhua et al. [114] Japan Japanese CYP3A5 rs776746 3, 4 1, 2, 3
BOO = bladder outlet obstruction; DRE = digital rectal examination; GWAS = genome-wide association study; PSA = prostate-speciﬁc antigen; SNP = single
nucleotide polymorphism; TRUS = transrectal ultrasound.
* Assessments of descent/ethnicity/race as speciﬁed in primary publications, or from additional data from authors, or assumed for countries with low ethnic
heterogeneity including Finland, Korea, and Japan.
y Listed SNPs are only those that could be included in meta-analyses. Helfand et al. [42] assessed 38 SNPs prioritized from prostate carcinoma GWAS.
Gudmundsson et al. [41] assessed 15 SNPs prioritized from PSA GWAS.
z Same results reported for rs2234693 in Gupta et al. [64] and Sobti et al. [98].
E U RO P E AN URO LOG Y 6 6 ( 2 0 1 4 ) 7 5 2 – 7 6 8758participants, tested an overlapping set of eight prostate
cancer or PSA-risk SNPs prioritized from GWAS for an
association with LUTS or LUTS medication use. Of these,
only rs2736098 demonstrated a nominally significant
pooled association but with a small effect size (OR: 1.25;
95% CI, 1.04–1.20) and high heterogeneity (I2 = 87.1%)
(Fig. 6). Again, this confersweak epidemiological credibility.3.5. VDR
Low vitamin D can be considered one component of the
metabolic syndrome. Low vitamin D levels decrease
prostate apoptosis and are associated with BPH [43]. One
vitamin D3 analog has also been shown to delay prostate
growth in men with BPH [44]. The vitamin D receptor has a
Table 2 – Interim Venice assessments of epidemiological credibility for each meta-analysis
Gene dbSNP ID or
other identiﬁer
No. of
studies
MAF
sample*
Pooled OR§
(95% CI)
I2, % HWE** Proteus
effect
Harborda
test p
Risk of bias
in genotyping
Risk of
population
stratiﬁcation
Venice
rating
Overall
credibility
ACE rs4340 2 334 0.66
(0.49–0.90)
91.9 None Yes NA Low/Unknown Low BCA Weak
AR CAG repeat 9 4044b 0.05
(0.12 to 0.02)
47.4 NA Yes 0.88 Low/Unknown Possible/Highz ACB Weak
GGN repeat 2 333b 0.12
(0.10 to 0.34)
0.0 NA No NA Low/Unknown Possible/Highz BCB Weak
CYP17 rs743572 5 659 0.96y
(0.69–1.34)
78.7 [98] Yes 0.33 Low/Unknown Low ACB Weak
ELAC2 rs4792311 4 675 1.02
(0.86–1.21)
1.2 [36,100] No 0.55 Possible/High Low BCC Weak
rs5030739 2 71 1.75
(1.22–2.49)
0.0 Unknown No NA Low Low CBA Weak
FGFR2 rs10788160 2 9000 1.02
(0.96–1.09)
0.0 Unknown No NA Low Low ACA Weak
FGFR4 rs351855 2 281 1.08
(0.87–1.35)
71.4 None No NA Low/Unknown Low BCB Weak
GSTM1 Null/Deletion CNV 6 695 2.08y
(1.37–3.16)
74.3 NA No 0.79 Low Low/None BCA Weak
GSTP1 rs1695 2 192 0.93
(0.69–1.26)
0.0 None No No Low/Unknown Low BCA Weak
GSTT1 Null/deletion CNV 6 356 1.02y
(0.71–1.46)
49.9 NA Yes 0.58 Low/Unknown Low BCB Weak
HNF1B rs4430796 2 18 000 1.00
(0.93–1.07)
51.5 Unknown No NA Low Low ACA Weak
IFNG rs2430561 2 532 0.88
(0.70–1.1)
55.2 None No NA Low/Unknown Low BCA Weak
IFBP3 rs2854744 2 731 1.14
(0.96–1.36)
27.9 None No NA Low Low BCA Weak
IL10 rs1800896 2 541 1.09
(0.86–1.38)
0.0 [71,91] No NA Possible/High Low BCC Weak
IL1RN rs2234663 3 510 1.64y
(0.83–3.22)
87.4 Unknown Yes 0.17 Low/Unknown Low BCB Weak
IL4 rs2234664 2 424 0.98
(0.76–1.27)
86.6 [71,72] No NA Possible/High Low BCC Weak
KLK3 rs266882 3 924 0.98y
(0.65–1.47)
78.3 None No 0.28 Low/Unknown Low BCB Weak
rs17632542 2 2000 1.08
(0.96–1.20)
0.0 Unknown No NA Low Low ACA Weak
rs2735839 2 4000 1.06
(0.88–1.26)
0.0 Unknown No NA Low Low ACA Weak
MSMB rs10993994 2 13 000 0.96
(0.91–1.02)
0.0 Unknown No NA Low Low ACA Weak
RP11–38 rs1447295 2 276 0.83
(0.60–1.14)
0.0 None No NA Low/Unknown Low BCB Weak
rs6983267 2 675 1.09
(0.89–1.37)
85.5 None Yes NA Low/Unknown Low BCB Weak
SRD5A2 rs523349 4 663 1.05
(0.87–1.26)
0.0 None No 0.21 Low/Unknown Possible/Highz BCC Weak
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Gene dbSNP ID or
other identiﬁer
No. of
studies
MAF
sample*
Pooled OR§
(95% CI)
I2, % HWE** Proteus
effect
Harborda
test p
Risk of bias
in genotyping
Risk of
population
stratiﬁcation
Venice
rating
Overall
credibility
rs9282858 3 69 1.82y
(0.83–3.98)
45.2 None No 0.58 Low/Unknown Possible/Highz BCC Weak
TA(n) repeat 2 251 0.95
(0.73–1.23)
66.6 NA No NA Unknown Possible/Highz BCC Weak
TBX3 rs11067228 2 18 000 1.02
(0.97–1.08)
0.0 Unknown No NA Low Low ACA Weak
TERT rs2736098 2 10 000 1.25
(1.04–1.20)
87.1 Unknown No NA Low Low ACA Weak
rs401681 2 18 000 1.05
(0.99–1.11)
0.0 Unknown No NA Low Low ACA Weak
TGFB1 rs1800470 4 993 1.04y
(0.73–1.47)
79.8 [71] No 0.38 Low/Unknown Low BCB Weak
TNFA rs1800629 2 248 0.94
(0.69–1.28)
0.0 [91] No NA Low/Unknown Low BCC Weak
VDR rs731236 5 409 0.64y
(0.49–0.83)
27.2 [50] No 0.54 Low/Unknown Low BBB Moderate
rs1544410 3 417 0.77y
(0.54–1.09)
45.9 [49] Yes 0.94 Low/Unknown Low BCC Weak
rs7975232 2 364 1.10
(0.81–1.48)
38.6 None No NA Unknown Low BCB Weak
rs10735810 2 646 0.91
(0.75–1.12)
0.0 [50] No NA Low Low BCB Weak
HWE = Hardy-Weinberg equilibrium; MAF = minor allele frequency; OR = odds ratio; SNP = single nucleotide polymorphism.
Three-letter code corresponds to A through C ratings of the amount of evidence, its consistency, and its protection from bias (see Supplemental Fig. 1).
* Pooled sample size of participants with minor allele or nominal risk variant.
** Checked in controls and meta-analysis rechecked excluding studies with signiﬁcant departure. References refer to studies with signiﬁcant departure from HWE.
z Studies each include populations with mixed descent groups without reported adjustment.
§ SMD per copy for short tandem repeats.
a Egger test for short tandem repeats.
b Total sample size reported for short tandem repeats.
y Weights are from random effects analysis.
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Fig. 2 – Forest plot of statistically significant single nucleotide polymorphisms in pooled analyses. Plots presented as risk associated with minor alleles.
CI = confidence interval; OR = odds ratio.
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Author Year
Sierra Diaz
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2009
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OR (95% CI) Weight
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0.82 (0.59–1.12)    78.83
.1                                                                1                  2
0.66 (0.49–0.90)    100.00Overall (I2 = 91.9%, p = 0.000)
Fig. 3 – Forest plot of studies reporting associations between the rs4340 288 bp insertion polymorphism of the angiotensin-converting enzyme gene and
lower urinary tract symptoms. Plot presented as risk associated with insertion allele.
CI = confidence interval; OR = odds ratio.
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Study Year
rs4792311
Rokman
Takahashi
lzmirli
Sobti
2001
%
2.81
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100.00
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2.06 (0.88–4.82)
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1.02 (0.86–1.21)
2003
2011
2011
Subtotal (I2 = 1.2%, p = 0.386)
rs5030739
Rokman 2001
Izmirli 2011
Subtotal (I2 = 0.0%, p = 0.740)
Fig. 4 – Forest plot of studies reporting associations between the rs5030739 and rs4792311 single nucleotide polymorphisms of the elaC homolog 2
(Escherichia coli) gene and lower urinary tract symptoms. Plot presented as risk associated with minor alleles.
CI = confidence interval; OR = odds ratio.
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Fig. 5 – Forest plot of studies reporting associations between the null allele of the glutathione S-transferase mu 1 gene and lower urinary tract symptoms.
Plot presented as risk associated with deletion/null allele.
CI = confidence interval; OR = odds ratio.
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Fig. 6 – Forest plots of overlapping set of eight single nucleotide polymorphisms (SNPs) prioritized from prostate cancer or prostate-specific antigen (PSA)
genome-wide association studies and tested for association with lower urinary tract symptoms (LUTS) in Icelandic (Gudmundsson et al. [41]) and US
(Helfand et al. [42]) populations. Top line shows significant pooled associations between the rs2736098 SNP of the telomerase reverse transcriptase gene
and LUTS. All plots presented as risk associated with minor alleles.
CI = confidence interval; OR = odds ratio.
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Fig. 7 – Forest plot of studies reporting associations between single nucleotide polymorphisms of the vitamin D receptor gene and lower urinary tract
symptoms. Plots presented as risk associated with minor alleles.
CI = confidence interval; D + L = DerSimonian & Laird; M-H = Mantel-Haenszel; OR = odds ratio.
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investigated in association with LUTS or prostate cancer.
One noncoding SNP in the 30 region, rs731236, which is
associatedwith increased serum vitamin D levels, may have
a protective benefit against prostate cancer [45], at least in
some populations. In five studies in ethnically diverse
populations of its association with LUTS [46–50], there was
a consistent protective effect of theminor allele, with a large
pooled effect size (OR: 0.64; 95% CI, 0.49–0.83) and
moderate heterogeneity (I2 = 27.2%) (Fig. 7). Uniquely
among statistically significant findings, this association
was both consistent across studies, with an adequate pooled
sample of the minor allele (n = 409), and no apparent
sources of bias in the primary studies, conferring moderate
epidemiological credibility. One other SNP, in near perfect
linkage disequilibrium, in the same gene (rs1544410)
demonstrated a near significant effect in a random effects
pooled analysis of Japanese, Thai, and Indian populations
(OR: 0.77; 95% CI, 0.54–1.09) with moderate heterogeneity
(I2 = 45.9%). In a prespecified analysis restricted to the two
East Asian populations, the pooled effect size was large (OR:
0.62; 95% CI, 0.44–0.87), with no heterogeneity, suggesting
the possibility of an effect specific to East Asian populations.
Other SNPs tested in the same gene (rs7975232 and
rs10735810) showed no significant pooled effects.3.6. Publication and other biases
Most of the possible meta-analyses included fewer than five
studies, providing low power for conventional measures of
funnel plot asymmetry. Consequently, the Harbord test
demonstrated no evidence of small study bias or publication
bias (p values all >0.1) for any individual meta-analysis.
Howeveracross the fieldasawhole,weobservedanumberof
phenomena consistent with potential publication bias and
selective reporting. The most studied polymorphism, the
CAG repeat in the androgen receptor, provides a salient
example.We included nine case-control studies, of which all
but one contributed to meta-analysis. This meta-analysis
demonstrates a marked Proteus effect [51], with the original
papers based on US populations demonstrating a significant
association between short CAG repeats and LUTS [52,53],
which despite repeated studies was never replicated. In this
instance the initial estimates of a significant associationmay
have resulted from unaddressed population stratification.
This pattern was typical, with many studies with either
obvious problems with departure from the Hardy-Weinberg
equilibrium (usually with limited information about geno-
typing quality control), potential for population stratifica-
tion, or selective use of analyses inconsistent with expected
modes of inheritance (Table 2).
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The strengths of this review include a contemporary and
comprehensive search of both published and unpublished
studies, applying explicit criteria to potentially eligible
studies and using standardized piloted data forms for data
collection guided by written instructions, and an unbiased
assessment and synthesis of reported associations. We
followed a prespecified data analysis plan and successfully
contacted many authors for clarifications and additional
data.
3.8. Limitations
Among the challenges faced in this reviewwas the inclusion
of studies with varying diagnostic criteria. There is a huge
disparity between symptomatic and objective findings for
LUTS that is further compounded by a disparity in the
standardization of terminology and diagnostic criteria used
in studies. We excluded studies using only surrogate
phenotypes such as PSA, prostate volume, or histology;
however, we included studies with a wide range of
symptomatic case definitions including definitions using
extensively validated questionnaires, definitions based only
on clinical interview, and definitions based on patterns of
treatment seeking or use of LUTS surgery. Both LUTS in
aggregate and the individual symptoms themselves may
have multiple underlying causes, and these syntheses may
therefore include participants not only with diverse
presentations but also with diverse underlying etiologies
for those symptoms.
With the exception of the studies reported in Figure 6,
the meta-analyses each include <1000 participants in total
and therefore provide adequate power only for associations
with large effect size (approximately OR 0.6 or OR1.8).
Furthermore, most meta-analyses include fewer than five
studies, providing limited scope for subgroup analyses. It is
therefore possible that smaller effect sizes or ethnicity-
specific associations have been missed in these syntheses.
3.9. Implications for clinical practice
With substantial risk of bias for most replicable associa-
tions, and without clear evidence of effect modification
from known environmental risks for male LUTS, it would be
inadvisable to risk stratify patients on the basis of these
genotypes. Neither routine nor selective use of these tests in
clinical practice can currently be recommended, pending
further trials.
The widespread availability of direct-to-consumer test-
ing means some patients may present with questions about
the implications of these polymorphisms. Clinicians should
be not only aware of the putative risks associated with
these variants, but also about the substantial uncertainty
regarding these associations due to risks of bias in the
primary studies.
The complexity of the pathophysiologic and pharmaco-
logic mechanisms underlying the development of male
LUTSmakes them a promising target for stratifiedmedicine.LUTS can display remarkable fluctuation over time [54], and
therefore the optimal timing of intervention can be difficult
to ascertain. Genetic variants can potentially provide stable
and unconfounded estimates of risk of incidence or
progression of LUTS. In the future, genetic counseling
may therefore play one part of an investigation when
considering the implications of intervention for male LUTS,
and it may help target younger men for primary or
secondary prevention. At this time clinicians should
continue to use a family history of LUTS as a simple but
powerful marker of future risk.
3.10. Implications for future research
The potential biases and failed replications among candi-
date gene studies we identify here are hardly unique to the
urologic literature [55], but clear guidance now exists for
the reporting and synthesis of GWAS [56]. Future studies in
this field should try to minimize such catastrophic sources
of bias, and urologic journals could adopt relevant reporting
guidance.
Principal among the sourcesof imprecision identifiedhere
are inadequate sample sizes, lack of genotyping quality
control, and inadequate adjustment for populations from
heterogeneous descent groups. Each of these concerns could
be overcome using large-scale GWAS with appropriate
attention to population stratification. GWAS have been
successfully used to identify many novel susceptibility
variants for prostate cancer, and this technique should
now be applied to male LUTS, using population-based
cohorts with relevant phenotypes. The variants identified
here should be prioritized for replication in future GWAS
[57]. As new susceptibility variants are discovered, inclusion
of DNA collections in current interventional trials in LUTS
may provide significant additional power as a potential
confounder.
4. Conclusions
Family studies and twin studies have provided convincing
evidence for a genetic predisposition tomale LUTS. However,
despite a large research literature, this systematic reviewand
meta-analysis using the Venice criteria has identified very
fewgenetic variants that have been reliably replicated across
populations. We found only one, the common rs731236
variant of the vitamin D receptor, credibly associated with
LUTS. The currently identified genetic associations explain
onlya tiny fractionof theheritability. Thediscoveryof further
risk variants should both help to explain the complex
pathophysiology of these symptoms and provide a route to
effective primary prevention.
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